Roche Holding (SWX:ROG) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ROG Aperçu des actions

Roche Holding AG exerce des activités pharmaceutiques et diagnostiques en Europe, en Amérique du Nord, en Amérique latine, en Asie, en Afrique, en Australie et en Océanie.

A propos de l'entreprise

ROG analyse fondamentale
Score flocon de neige
Évaluation	5/6
Croissance future	2/6
Performances passées	0/6
Santé financière	3/6
Dividendes	5/6

Récompenses

Se négocie à 63.4% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 11.15% par an

Verse un dividende fiable de 3.39%

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

A un niveau d'endettement élevé

Des éléments non récurrents importants ayant un impact sur les résultats financiers

Roche Holding AG Concurrents

Novartis

SWX:NOVN

CHF 198.3b

Dottikon ES Holding

SWX:DESN

CHF 3.6b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.2b

Merck

NYSE:MRK

US$288.2b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Roche Holding
Historique des cours de bourse
Prix actuel de l'action	CHF 272.20
Plus haut sur 52 semaines	CHF 288.20
Plus bas sur 52 semaines	CHF 212.90
Bêta	0.15
1Variation sur 1 mois	-5.22%
Variation sur 3 mois	8.84%
Variation sur 1 an	8.68%
3Variation sur 3 ans	-21.16%
Variation sur 5 ans	-4.86%
Évolution depuis l'introduction en bourse	942.91%

Nouvelles et mises à jour récentes

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Rendement pour les actionnaires

	ROG	CH Pharmaceuticals	CH Marché
7D	1.1%	-0.09%	2.4%
1Y	8.7%	11.0%	10.1%

Rendement vs Industrie: ROG a sous-performé le secteur Swiss Pharmaceuticals qui a rapporté 20.6 % au cours de l'année écoulée.

Rendement vs marché: ROG a sous-performé le marché Swiss qui a rapporté 10.1 % au cours de l'année écoulée.

Volatilité des prix

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	3.1%
Pharmaceuticals Industry Average Movement	3.4%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	6.7%
10% least volatile stocks in CH Market	1.6%

Cours de l'action stable: ROG n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ROG ( 3% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG exerce des activités pharmaceutiques et diagnostiques en Europe, en Amérique du Nord, en Amérique latine, en Asie, en Afrique, en Australie et en Océanie. L'entreprise propose des produits pharmaceutiques dans les domaines thérapeutiques suivants : anémie, tumeurs sanguines et solides, dermatologie, hémophilie, maladies inflammatoires et auto-immunes, troubles neurologiques, ophtalmologie, troubles respiratoires et transplantation. Elle développe également des produits pour divers domaines thérapeutiques.

Roche Holding AG Résumé des fondamentaux

Comment les bénéfices et les revenus de Roche Holding se comparent-ils à sa capitalisation boursière ?
ROG statistiques fondamentales
Capitalisation boursière	CHF 219.00b
Bénéfices(TTM)	CHF 10.62b
Recettes(TTM)	CHF 60.58b

20.4x

Ratio P/E

3.6x

Ratio P/S

Le site ROG est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ROG compte de résultat (TTM)
Recettes	CHF 60.58b
Coût des recettes	CHF 15.43b
Marge brute	CHF 45.16b
Autres dépenses	CHF 34.54b
Les revenus	CHF 10.62b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	13.33
Marge brute	74.54%
Marge bénéficiaire nette	17.53%
Ratio dettes/capitaux propres	104.8%

Quelles ont été les performances à long terme de ROG?

Voir les performances historiques et les comparaisons

Dividendes

3.5%

Rendement actuel des dividendes

72%

Ratio de distribution

ROG Aperçu des actions

Récompenses

Analyse des risques

Roche Holding AG Concurrents

SWX:NOVN

CHF 198.3b

SWX:DESN

CHF 3.6b

SWX:COPN

CHF 1.2b

NYSE:MRK

US$288.2b

Historique des prix et performances

Nouvelles et mises à jour récentes

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

Recent updates

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023